Apimeds Pharmaceuticals US, Inc. (APUS)
| Market Cap | 40.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.42M |
| Shares Out | 11.52M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About APUS
Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003 and now we will ... [Read more]
News
Inflammation-focused biotech Apimeds Pharmaceuticals US files for a $12 million IPO
Apimeds Pharmaceuticals US, a clinical stage biotech developing a bee venom-based treatment for inflammation, filed on Wednesday with the SEC to raise up to $12 million in an initial public offering.
Apimeds Pharmaceuticals US IPO Registration Document (S-1)
Apimeds Pharmaceuticals US has filed to go public with an IPO on the NYSE American